MRX-34
- Generic Name
- MRX-34
Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Mirna Therapeutics, Inc.
- Registration Number
- NCT02862145
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Phase 1
Terminated
- Conditions
- LymphomaNSCLCSCLCRenal Cell CarcinomaPrimary Liver CancerMelanomaMultiple Myeloma
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Mirna Therapeutics, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01829971
- Locations
- 🇺🇸
Texas Oncology Dallas, Dallas, Texas, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Uthscsa/Ctrc, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath